Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment

Giulia Petroni, Aitziber Buqué, Lisa M. Coussens, Lorenzo Galluzzi

Research output: Contribution to journalReview articlepeer-review

42 Scopus citations


Immune checkpoint inhibitors (ICIs) have revolutionized the clinical management of multiple tumours. However, only a few patients respond to ICIs, which has generated considerable interest in the identification of resistance mechanisms. One such mechanism reflects the ability of various oncogenic pathways, as well as stress response pathways required for the survival of transformed cells (a situation commonly referred to as ‘non-oncogene addiction’), to support tumour progression not only by providing malignant cells with survival and/or proliferation advantages, but also by establishing immunologically ‘cold’ tumour microenvironments (TMEs). Thus, both oncogene and non-oncogene addiction stand out as promising targets to robustly inflame the TME and potentially enable superior responses to ICIs.

Original languageEnglish (US)
Pages (from-to)440-462
Number of pages23
JournalNature Reviews Drug Discovery
Issue number6
StatePublished - Jun 2022

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment'. Together they form a unique fingerprint.

Cite this